The governing board of the California stem cell agency last night rejected appeals by two applicants -- OncoMed Pharmaceuticals of Redwood City and Albert Wong of Stanford -- in the $200 million disease team round.
Both petitions generated little discussion. You can find more on their petitions here and here.
The board also approved changes in its intellectual property and grant administration rules. Both proposals will now enter the state's official administrative law process for more comment and possible change.
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss
Recommendation and review posted by Fredricko
